Pancreatic gene variants potentially associated with dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes

被引:6
|
作者
Jamaluddin, Jazlina Liza [1 ]
Huri, Hasniza Zaman [1 ,2 ]
Vethakkan, Shireene Ratna [3 ]
Mustafa, Norlaila [4 ]
机构
[1] Univ Malaya, Fac Med, Dept Pharm, Kuala Lumpur 50603, Malaysia
[2] Univ Malaya, Med Ctr, Clin Invest Ctr, Kuala Lumpur 59100, Malaysia
[3] Univ Malaya, Fac Med, Dept Med, Endocrinol Unit, Kuala Lumpur 50603, Malaysia
[4] Natl Univ Malaysia, Fac Med, Dept Med, Endocrinol Unit, Kuala Lumpur 56000, Malaysia
关键词
ABCC8; dipeptidyl peptidase-4 inhibitors; KCNJ11; KCNQ1; MTNR1B; PAX4; TCF7L2; WFS1; GLUCAGON-LIKE PEPTIDE-1; TRANSCRIPTION-FACTOR-7-LIKE-2; TCF7L2; GENE; TRANSCRIPTION FACTOR PAX4; BETA-CELL FUNCTION; K-ATP CHANNELS; INSULIN-SECRETION; INCREASED RISK; INCRETINS GIP; GLUCOSE; GLP-1;
D O I
10.2217/pgs.13.234
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the adult pancreas, the expression of the genes PAX4, KCNQ1, TCF7L2, KCNJ11, ABCC8, MTNR1B and WFS1 are mainly restricted to cells to maintain glucose homeostasis. We have identified these genes as the main regulators of incretin-mediated actions, and therefore they may potentially influence the response of DPP-4 inhibitors. This review represents the first detailed exploration of pancreatic -cell genes and their variant mechanisms, which could potentially affect the response of DPP-4 inhibitors in Type 2 diabetes. We have focused on the signaling pathways of these genes to understand their roles in gastrointestinal incretin-mediated effects; and finally, we sought to associate gene mechanisms with their Type 2 diabetes risk variants to predict the responses of DPP-4 inhibitors for this disease.
引用
收藏
页码:235 / 249
页数:15
相关论文
共 50 条